KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--
Trevena, Inc. (
“We’re pleased to have had the opportunity at the ASA meeting to share our phase 2 clinical data in moderate to severe acute pain patients,” said David Soergel, M.D., Trevena’s chief medical officer. “As outlined in the podium presentations, oliceridine may become a valuable alternative to conventional IV opioids in the hospital.”
Two oral podium presentations reviewed results from Phase 2 studies of oliceridine, including comparisons of oliceridine to morphine. Dr. Jianguo Cheng, M.D., Ph.D, Professor of Anesthesiology at Case Western Reserve University presented data from Trevena’s Phase 2b abdominoplasty study, including analyses of dosing interruptions showing a favorable profile of oliceridine compared to morphine when both drugs were administered by patient-controlled analgesia. Dr. Eugene R. Viscusi, M.D., Professor of Anesthesiology at the Sidney Kimmel Medical College at Thomas Jefferson University presented data from Trevena’s Phase 2 bunionectomy study, including observation of faster onset of pain relief with oliceridine than with morphine. Data from the two presentations complement previously presented Phase 2b data showing that oliceridine reduced pain to a similar extent as morphine, but with fewer adverse events including nausea, vomiting, and respiratory events.
The company also was pleased to sponsor an accredited CME symposium entitled “Gaining Insight into Emerging Pain Management Therapies in an Acute Setting.”
Investor Relations Webcast: “Oliceridine and Unmet Needs in Injectable Analgesia”
On October 24, 2016, the company hosted an investor event that featured presentations and a panel discussion with three medical experts representing key stakeholders in hospital acute pain management:
- Timothy Beard, M.D., FACS, Chair of Department of Surgery, Bend...